These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 8717469

  • 1. The development of Casodex (bicalutamide): preclinical studies.
    Furr BJ.
    Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
    Furr BJ.
    Horm Res; 1989; 32 Suppl 1():69-76. PubMed ID: 2533159
    [Abstract] [Full Text] [Related]

  • 4. Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.
    Maucher A, von Angerer E.
    J Cancer Res Clin Oncol; 1993; 119(11):669-74. PubMed ID: 8349724
    [Abstract] [Full Text] [Related]

  • 5. Clinical progress with a new antiandrogen, Casodex (bicalutamide).
    Blackledge GR.
    Eur Urol; 1996; 29 Suppl 2():96-104. PubMed ID: 8717470
    [Abstract] [Full Text] [Related]

  • 6. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
    Simard J, Singh SM, Labrie F.
    Urology; 1997 Apr; 49(4):580-6; discussion 586-9. PubMed ID: 9111629
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bicalutamide dosages used in the treatment of prostate cancer.
    Kolvenbag GJ, Nash A.
    Prostate; 1999 Apr 01; 39(1):47-53. PubMed ID: 10221266
    [Abstract] [Full Text] [Related]

  • 10. Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer.
    Blackledge GR, Cockshott ID, Furr BJ.
    Eur Urol; 1997 Apr 01; 31 Suppl 2():30-9. PubMed ID: 9074908
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Casodex: preclinical studies and controversies.
    Furr BJ.
    Ann N Y Acad Sci; 1995 Jun 12; 761():79-96. PubMed ID: 7625752
    [No Abstract] [Full Text] [Related]

  • 13. Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen.
    Sarosdy MF.
    Anticancer Drugs; 1999 Oct 12; 10(9):791-6. PubMed ID: 10587288
    [Abstract] [Full Text] [Related]

  • 14. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model.
    Hobisch A, Hoffmann J, Lambrinidis L, Eder IE, Bartsch G, Klocker H, Culig Z.
    Urol Int; 2000 Oct 12; 65(2):73-9. PubMed ID: 11025427
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Current clinical studies with a new nonsteroidal antiandrogen, Casodex.
    Kaisary AV.
    Prostate Suppl; 1994 Oct 12; 5():27-33. PubMed ID: 8172713
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity.
    Luo S, Martel C, Chen C, Labrie C, Candas B, Singh SM, Labrie F.
    Urology; 1997 Dec 12; 50(6):913-9. PubMed ID: 9426723
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.